BIOLASE Stock Forecast, Price & News

BIOLASE (NASDAQ:BIOL) Frequently Asked Questions

Is BIOLASE a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOLASE stock.
View analyst ratings for BIOLASE or view top-rated stocks.

How has BIOLASE's stock price been impacted by Coronavirus (COVID-19)?

BIOLASE's stock was trading at $0.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BIOL stock has decreased by 28.8% and is now trading at $0.4130.
View which stocks have been most impacted by COVID-19.

When is BIOLASE's next earnings date?

BIOLASE is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for BIOLASE.

How were BIOLASE's earnings last quarter?

BIOLASE, Inc. (NASDAQ:BIOL) announced its quarterly earnings results on Wednesday, November, 10th. The medical technology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. BIOLASE had a negative trailing twelve-month return on equity of 74.97% and a negative net margin of 48.22%. During the same quarter in the prior year, the business earned ($0.21) earnings per share.
View BIOLASE's earnings history.

When did BIOLASE's stock split? How did BIOLASE's stock split work?

Shares of BIOLASE reverse split on the morning of Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.

What guidance has BIOLASE issued on next quarter's earnings?

BIOLASE updated its fourth quarter 2021 earnings guidance on Wednesday, December, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $10.20 M-, compared to the consensus revenue estimate of $10.62 million.

What price target have analysts set for BIOL?

3 analysts have issued 1 year target prices for BIOLASE's shares. Their forecasts range from $1.15 to $3.00. On average, they expect BIOLASE's share price to reach $2.05 in the next twelve months. This suggests a possible upside of 396.4% from the stock's current price.
View analysts' price targets for BIOLASE or view top-rated stocks among Wall Street analysts.

Who are BIOLASE's key executives?

BIOLASE's management team includes the following people:

• John R. Beaver, President, Chief Executive Officer & Director
• William E. Brown, Vice President-Business Development
• Richard R. Whipp, Vice President-Operations
• Samuel B. Low, Chief Dental Officer, VP-Dental & Clinical Affairs
• Matthew Wilson, Vice President-Human Resources

What is Todd Norbe's approval rating as BIOLASE's CEO?

8 employees have rated BIOLASE CEO Todd Norbe on Glassdoor.com. Todd Norbe has an approval rating of 13% among BIOLASE's employees. This puts Todd Norbe in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of BIOLASE's key competitors?

Some companies that are related to BIOLASE include Straumann (SAUHF), Sartorius Aktiengesellschaft (SARTF), DENTSPLY SIRONA (XRAY), Envista (NVST), SmileDirectClub (SDC), Item 9 Labs (INLB), Remedent (REMI), American Medical Technologies (ADLI) and Lancer Orthodontics (LANZ).
View all of BIOL's competitors.

What other stocks do shareholders of BIOLASE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brands International (GNUS).

What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

Who are BIOLASE's major shareholders?

BIOLASE's stock is owned by many different retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.04%), Geode Capital Management LLC (0.88%), GSA Capital Partners LLP (0.83%), Essex Investment Management Co. LLC (0.53%), Marshall Wace LLP (0.50%) and Two Sigma Advisers LP (0.26%). Company insiders that own BIOLASE stock include Jack W Schuler, John R Beaver, John R Beaver and Larry N Feinberg.
View institutional ownership trends for BIOLASE.

Which major investors are buying BIOLASE stock?

BIOL stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, GSA Capital Partners LLP, Essex Investment Management Co. LLC, Marshall Wace LLP, Two Sigma Advisers LP, Geode Capital Management LLC, Two Sigma Investments LP, and Citadel Advisors LLC.
View insider buying and selling activity for BIOLASE or or view top insider-buying stocks.

How do I buy shares of BIOLASE?

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BIOLASE's stock price today?

One share of BIOL stock can currently be purchased for approximately $0.41.

How much money does BIOLASE make?

BIOLASE has a market capitalization of $63.30 million and generates $22.78 million in revenue each year. The medical technology company earns $-16.83 million in net income (profit) each year or ($0.15) on an earnings per share basis.

How many employees does BIOLASE have?

BIOLASE employs 135 workers across the globe.

What is BIOLASE's official website?

The official website for BIOLASE is www.biolase.com.

Where are BIOLASE's headquarters?

BIOLASE is headquartered at 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610.

How can I contact BIOLASE?

BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The medical technology company can be reached via phone at (949) 361-1200, via email at [email protected], or via fax at 949-273-6677.